Novavax says COVID vaccine triggers immune response to Omicron variant | Inquirer News

Novavax says COVID vaccine triggers immune response to Omicron variant

/ 06:27 AM December 23, 2021

Novavax says COVID vaccine triggers immune response to Omicron variant

FILE PHOTO: Vials labeled “VACCINE Coronavirus COVID-19” and a syringe are seen in front of a displayed Novavax logo in this illustration taken December 11, 2021. REUTERS/Dado Ruvic/Illustration

Novavax Inc’s COVID-19 vaccine is effective in generating an immune response against the Omicron variant, according to early data published Wednesday, suggesting that the U.S. drugmaker’s existing COVID-19 vaccine can help combat the new Omicron variant.

Novavax’s two-dose, protein-based vaccine was authorized for use this week by European Union regulators and the World Health Organization. It has previously been approved by countries including Indonesia and the Philippines but not the United States.

Article continues after this advertisement

Novavax said that receiving an additional booster dose of Novavax’s vaccine further increased people’s immune response to Omicron. The data was taken from Novavax’s ongoing studies of its vaccine’s effectiveness in adolescents and as a booster.

FEATURED STORIES

“We are encouraged that boosted responses against all variants were comparable to those associated with high vaccine efficacy in our Phase 3 clinical trials,” said Gregory M. Glenn, Novavax’s president of research and development.

Other COVID-19 vaccine manufacturers, including Pfizer Inc. and Moderna Inc., also increase immune responses to Omicron, early data from those companies has shown. Resistance in all cases is stronger in people who have received an additional booster dose.

Article continues after this advertisement

Novavax is working on developing an Omicron-specific vaccine and said Wednesday it expects to begin manufacturing doses of the variant-specific shot in January.

Article continues after this advertisement

The drugmaker will start shipping vaccines to the EU’s 27 member states in January as part of its deal to supply up to 200 million doses.

The company will also begin shipments in early 2022 to COVAX, a vaccine distribution mechanism overseen by WHO that allocates COVID-19 shots to poorer countries. Novavax and its partner, Serum Institute of India, have agreed to send COVAX more than 1.1 billion doses of Novavax’s vaccine.

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: COVID-19, Novavax, Omicron, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.